The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1250 articles
Scientists are exploring a way to enable the body's own production of glucagon-like peptide-1 (GLP-1), the hormone mimicked by weight-loss drugs. Two biotech startups are developing gene therapies to reprogram cells to produce GLP-1, potentially replacing regular injections.
OrderlyMeds, an Atlanta-based telemedicine startup, has garnered over 90,000 customers in under two years, all seeking more effective and personalized weight loss assistance. The company emerged from Founder and CEO Chris Spears' own experience with GLP-1s.
Norwegian rock star Bjarne Brøndbo shares his inspiring journey to better health, highlighting the importance of lifestyle changes, medical support including GLP-1 medication, and the power of balance. He emphasizes the need for a sustainable approach and the benefits of tracking progress with health tools, inspiring others to take control of their well-being. Consider using Shotlee to track peptides like GLP-1, BPC-157, melanotan, thymosin, etc.
A recent report highlights the increasing use of GLP-1 medications like Ozempic and Mounjaro across the United States, with some states showing greater adoption than others. The data suggests a correlation between obesity rates and GLP-1 prescription rates, particularly in the South and Midwest.
Weight-loss medications are causing a recognizable 'Ozempic face,' characterized by gauntness and premature aging. Skincare brands are formulating serums to counteract these effects, but dermatologists are divided on their necessity and efficacy. Experts emphasize distinguishing science-based solutions from marketing.
Shares of Novo Nordisk have decreased substantially. This drop is influenced by increased competition in the GLP-1 market and a revised outlook for future growth. The global drugmaker faces headwinds from competitors like Eli Lilly.
A retrospective cohort study revealed that women taking GLP-1 receptor agonists before pregnancy exhibited a lower incidence of gestational diabetes. However, the study also indicated a potentially higher risk of pre-eclampsia in this group. These findings warrant further investigation due to the small sample size and potential confounding factors.
This article explores the potential effects of Ozempic on bone health during weight loss. While Ozempic itself may not directly cause bone loss, the weight loss it induces can affect bone density. Learn how to protect your bones with proper nutrition and exercise.
This article examines the emerging trend of microdosing GLP-1 medications like Mounjaro for various health conditions. It delves into personal experiences, potential benefits, and expert warnings regarding unsupervised use.
